Only a couple of years since the first sickle cell disease (SCD) gene therapies gained U.S. FDA approval, researchers are working to expand access for younger children, and to improve manufacturing ...
Biopharma financing activity from January through November reveals an environment that has cycled through dramatic peaks and ...
The overexpression of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) is tied to poor prognosis in several cancer ...
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic ...
The ALS Association has announced the recipients of its 2025 Hoffman ALS Clinical Trial Awards. These research grants, worth ...
Receptor-interacting protein kinase 1 (RIPK1) helps promote the survival of cancer cells, and degrading it can sensitize ...
Crescent Biopharma Inc. has announced a new partnership with Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. and reported ...
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to ...
After a more than 13-year period of stability with Janet Woodcock as the head of CDER, with Patrizia Cavazzoni taking charge ...
The U.S. FDA’s recent switch toward more routine use of generalist field investigators might be seen in some quarters as an attempt to do more with less, but a session on the topic at the Food and ...
Freenome Holdings Inc. reported it is going public via a special purpose acquisition company. The company said it expects to raise $330 million, which it plans to use for the 2026 launch of its ...
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback